Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 3/20 | 0.61 |
| ▸ | EPAS1 | Q99814 | 3/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 2/20 | 0.51 |
| ▸ | RAB9A | P51151 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1014092 | 0.85 | ABL1 (0.50) | HIF1AEPAS1KMT2ASMN1; SMN2HPGD | |
| SCHEMBL1011847 | 0.84 | MCHR1 (0.48) | HIF1AEPAS1KMT2ASMN1; SMN2MAPK1 | |
| SCHEMBL25062318 | 0.82 | HTT (0.63) | HIF1AEPAS1KMT2ASMN1; SMN2MAPK1 | |
| SCHEMBL1421404 | 0.81 | CTSB (0.50) | HIF1AEPAS1KMT2ASMN1; SMN2MAPK1 | |
| SCHEMBL1014280 | 0.81 | CYP2A13 (0.47) | HIF1AEPAS1KMT2ASMN1; SMN2MAPK1 | |
| SCHEMBL1014530 | 0.80 | MAPT (0.51) | KMT2ASMN1; SMN2MAPK1KDM4ELMNA | |
| SCHEMBL13674546 | 0.80 | LTA4H (0.46) | HIF1AEPAS1KMT2ASMN1; SMN2MAPK1 | |
| SCHEMBL1014528 | 0.80 | HTT (0.54) | KMT2ASMN1; SMN2LMNA | |
| SCHEMBL171628 | 0.80 | SMN1; SMN2 (0.81) | HIF1AEPAS1KMT2ASMN1; SMN2MAPK1 | |
| SCHEMBL25062364 | 0.80 | GSK3B (0.51) | HIF1AKMT2ASMN1; SMN2MAPK1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110034466-A1 | NOVEL FIVE-MEMBERED RING COMPOUND | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2011-02-10 | — | — | US | disclosed |
| EP-2272835-A1 | NOVEL FIVE-MEMBERED RING COMPOUND | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2011-01-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110034466-A1 | NOVEL FIVE-MEMBERED RING COMPOUND | CCL11, CCR1, CCR10 | HIF1A 4335/4885EPAS1 2986/4885KMT2A 4321/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.